

Protecting Your Femtech IP

Wednesday, November 30, 2022



Meet The Speakers



Giordana Mahn Of Counsel gmahn@fr.com





Jacqueline Tio Principal tio@fr.com



Overview

- What is Femtech?
- **Investments in Femtech**
- **Sex Differences Matter**
- **Protecting Your Femtech**
- Where are Women in IP?
- **Survey of Femtech IP Landscape 2022**
- **Questions**
- **Materials**
 - http://www.fr.com/webinars










What is Femtech?

What is femtech?







Investments in Femtech

Economic Outlook of the Industry

Market Opportunity


- Women are 51% of the population
- Women make 80% of the household healthcare decisions
- Women have 75-80% purchasing power
- Women consume approximately 80% of pharmaceuticals in the US¹



Economic Outlook of the Industry

Revenue forecast to reach 103 billion U.S. dollars by 2030


Femtech market size worldwide from 2021 to 2030 (in billion U.S. dollars)





Source: Statista Dossierplus on the Global Femtech Industry; Precedence Research; ID <u>1333181</u> Notes: Worldwide; 2022; *forecasted years

Forecasted Value of 2027 Worldwide Female Health Market





Bone health


22

Source: Statista Dossierplus on the Global Femtech Industry; Femtech Focus; ID 1303768

Notes: Worldwide; 2021

Notes: Amounts are in billion U.S. Dollars

Venture Funding in Femtech Companies





Source: Statista Dossierplus on the Global Femtech Industry; Rock Health; ID 1303968

Notes: United States; 2012 - August 31, 2021 Notes: Amounts are in million U.S. Dollars



Sex Differences Matter

Let's talk about sex (differences), baby!

There are differences in every tissue and organ system in the human body

- Mechanical workings of the heart
- Autoimmune disease
- Metabolizing drugs
- Lung capacity
- Reactions to vaccines
- Pain

- Cellular²
 - blood-serum bio-markers for autism,
 - proteins,
 - immune cells used to convey pain signals,
 - how cells die following a stroke,
 - Parkinson's disease,
 - brain ischemia,
 - aging of blood vessels,
 - cell response to stress



Let's talk about sex (differences), baby!

Women are Underrepresented in Research

- Until 1993, women of child-bearing age were excluded from participating in clinical drug trials
- In 1993, the US passed the National Institute of Health Revitalization Act to make excluding women in federally funded clinical trials illegal³
- 1987-2012, women made up 25% of participants across 31 landmark trials for congestive heart failure⁴
 - Startling because cardiac disease is the #1 killer of women
- In many cases, females aren't included in animal studies on female-prevalent diseases⁵
- Even if female animals are included, no guarantee data will be sex-analyzed in fact, 2/3 of the time results were not analyzed by sex⁶



Let's talk about sex (differences), baby!

Sex-Specific Drug Efficacy

- A 2005 review found that 79% of pain studies used only male mice⁷
- 2007, of the few studies that did involve rats or mice of both sexes, 54% revealed sexdependent drug effects⁸
- A 2001 report from the Government Accountability Organization found that out of 10 prescription drugs withdrawn from the market from 1997-2001, 8 were found to pose greater health risks for women⁹
 - 1/3 of which created sudden cardiac death in women not otherwise considered at risk
- Statins are some of the most prescribed drugs in America, yet they appear to have little benefit for the millions of women taking them¹⁰
- 2002, FDA's Center for Drug Evaluation and Research showed 'statistically significant differences between men and women in bioequivalence for most generic drugs compared with reference drugs.' 11





Protecting Your Femtech Assets

Where there is neglect, there is opportunity

White Space in Femtech


- Because of these sex differences, there is enormous opportunity in creating new treatments, diagnostics, and preventative care for various diseases and conditions that affect women
- Not just in health, but opportunity in new designs based on the female body
 - Cars and seatbelts are not designed for women's bodies, resulting in more deaths and serious injuries from car accidents than men
 - Women are more likely to experience motion sickness, generally, and also while using VR
 - PPE, tools, phones, keyboards, speech recognition software, etc.



What is Intellectual Property?

A category of intangible rights protecting commercially valuable products of the human intellect. A commercially valuable product of the human intellect, in a concrete or abstract form.

Black's Law Dictionary (11th ed. 2019)






Patents

- The right to exclude others from making, using, selling, offering for sale, and importing your patented invention
- General Requirements to Obtain a US Patent
 - Subject matter eligible
 - "whoever invents or discovers any new and useful process, machine, manufacture or composition of matter, or any new and useful improvement thereof, may obtain a patent therefore..." (35 U.S.C. §101)
 - Cannot patent law of nature, natural phenomenon, or an abstract idea
 - New (35 U.S.C. §102)
 - Not obvious to a person having ordinary skill in the art (35 U.S.C. §103)



Utility Patents – Digital Health Technologies


- Digital Health Innovations: Computer software and/or hardware innovations that process "medical information" related to an entity (e.g., a person or animal)
 - Machine learning model that has been trained to predict a likelihood of a particular patient characteristic
 - Ex: Using menstrual history data (including symptoms) to determine a daily workout routine





Utility Patents – Digital Health Technologies

- Digital Health Diagnostic Innovations: Computer software and/or hardware innovations that measure an attribute of an entity (e.g., a person or animal)
 - This can include measuring a biological attribute or measuring a change of a biological attribute
 - Ex: Measuring breast tissue composition, comparing to recorded tissue composition, providing test result of changes and instructions to follow up with your doctor for a breast health exam







Shown: Dotplot, source: https://https://www.bbc.com/news/technology-62807367

Utility Patents – Digital Therapeutics

- Digital Therapeutic Innovations: Computer software and/or hardware innovations that provide therapeutic content to an entity (e.g., a person or animal) that is configured to treat a symptom of the entity
 - Method of treatment claims (e.g., textual, audio, video content, haptic feedback, or a combination)
 - Example Hybrid System of Digital Therapeutic and Health Innovations: Wearable device that measures heart rhythms and detects symptoms of heart disease and alerts the user





Utility Patents – Improved Device

US 10,888,450, Menstrual cups and methods of use




FIG. 1

US10888450



1. A menstrual cup, comprising:

a rim having an upper portion, a lower portion, a first end, a second end, and an exterior surface, the rim defining a first lip adjacent the upper portion, the first lip extending along the exterior surface of the rim, the rim comprising silicone; and

a receptacle disposed adjacent and attached to the lower portion of the rim, the receptacle defining an interior surface, the interior surface comprising a textured pattern, the receptacle comprising silicone, wherein a slope of a first end of the receptacle adjacent to the first end of the rim is less than a slope of a second end of the receptacle adjacent to the second end of the rim;

wherein the first end of the rim extends away from the receptacle.

Design Patents

Ornamental appearance of your design





FIG. 1

D837980



D746452




FIG. 2

D832438

INTIMINA™ Ziggy Cup 2 – patent protected



Roll over image to zoom in

Intimina Ziggy Cup 2 - New Generation Ultra-Thin Flat-Fit Reusable Menstrual Disc (B)

Visit the INTIMINA Store

**** 98 ratings

Price: \$26.60 (\$26.60 / Count)

Get a \$200 Gift Card: Pay \$0.00 \$26.60 upon approval for the Amazon Prime Rewards Visa Card. No annual fee.

May be available at a lower price from other sellers, potentially without free Prime shipping.

Size: B

В \$31.26 \$28.00 (\$31.26 / Count) (\$28.00 / Count)

Size В

Brand INTIMINA Dark Pink Color Material Silicone Item Diameter 14 Centimeters

About this item

- · Upgraded design made of reinforced, flexible, 100% medical grade silicone, and it comes with an addition; ribbed tab for slip-
- · Inclusive sizes Ziggy Cup 2 now comes in sizes: size A (low cervix, light to medium flow) and size B (higher cervix, light to heavier flow)
- · Period protection Can be worn for up to 8 hours, and you can use it for up to 2 years. A reusable and reliable menstrual cup that can be worn during sex
- · Adapts to your body It's a high-capacity cup with a flexible,



Femtech in Law

Intellectual Property Regulatory Privacy





Where are Women in IP?

Where there is neglect, there is opportunity

Representation in Inventorship

- 0.4% of issued patents are directed to women's health
- In the field of biomedical patents, patents with women inventors are significantly more likely to focus on female diseases and conditions ¹²
- "Rough calculations suggest that if all the patents invented between 1976 and 2010 had been produced by men and women equally, then there would have been around **6,500 more female-focused inventions**."
- Quick Illustration: US Filed Patent Applications 1515 v. 304
 - 1515 related to penile pumps and implants vs. 304 related to menstrual cups and discs for collecting menstrual blood



Where there is neglect, there is opportunity

Representation in Inventorship

- Data on gender is not collected by the USPTO. Rather, to estimate patents issued to women inventors, the Institute for Women's Policy Research ("IWPR") relied on a commercial name matching software to guess the gender of the inventors in a 2016 report. This 2016 report found that "[i]n 1977 just over 1,500 domestic patents had at least one female inventor, but by 2010 the number of patents with at least one female inventor increased by 15 times to just under 23,000."13
- Another IWPR study found that while "the share of patents [in the US] with at least one woman inventor grew from 20.7 percent to 21.9 percent between 2016 and 2019, this improvement is smaller than that of other benchmarks of women's education and employment as scientists and engineers." 14




Women Inventors Stats in U.S. Are Still Behind


- In 2022, women make up 50.7% of U.S. college-educated workforce and as of 2020 represented 45% of STEM majors.
- But, women are only 27% of U.S. STEM workforce per 2021 census data
- Women inventor rate as of 2019 is only 13% in U.S. but as of 2021 is only 16.5% internationally



- Share of Women Inventors among all PCT Applications from 2001 2021
 - Data from WIPO IP Statistics Data Center, International Women's Day 2022 Presentation









Data from WIPO IP Statistics Data Center, International Women's Day 2022 Presentation





Data from WIPO IP Statistics Data Center, International Women's Day 2022 Presentation





Data from WIPO IP Statistics Data Center, International Women's Day 2022 Presentation





Survey of femtech IP landscape 2022

IP Landscape Survey

81 femtech companies

Includes companies based in U.S., Canada, United Kingdom, EU, and Israel

Sectors analyzed:

- Menstruation products
- Menopause products
- Digital health communities
- Apps
- Women-focused mechanical devices
- Egg freezing/IVF/fertility services

- Diagnostic/testing devices
- Birth control/nursing delivery
- Fertility/breastfeeding products
- Benefits platforms
- Biotech drug products
- Sexual and maternal health



IP Landscape Survey





IP Landscape Survey



1,622

Total Patents and **Published Applications**

Worldwide, includes expired patents



1559

Total Trademark Registrations

Worldwide, includes abandoned registrations



17
Total Copyright
Registrations

U.S. only



IP Landscape Survey

Breakdown by Companies

48%

have patents or patent applications 88%

have registered trademarks

7%

Have registered U.S. copyrights

Breakdown by Sectors

Patents

Companies in biotech drug products, mechanical devices, and menstruation products were more likely to have *patents*

Trademarks


All sectors had companies registering trademarks

Copyrights

All sectors less likely to have registered copyrights (U.S.)




Patents by Sector - 2022




Trademarks by Sector - 2022





Copyrights by Sector - 2022



"Soft IP" Revisited

1) Business assets that grow with company

- a) Registered ® and © gives you more teeth than unregistered rights
- b) Can copyright source code, websites, and most written content and trademark designs



US Reg. No. <u>2,184,128</u>

2) Start early! Trademarks are "first come, first serve"

CLEAR → FILE → USE → POLICE



US Reg. No. <u>3,936,105</u>



"Soft IP" Revisited

- **Keep your protections broad**
 - Example:
 - <u>Do</u> Class 9: downloadable podcasts in the field of business, entrepreneurship, health, wellness, and travel
 - Don't Class 9: downloadable podcasts in the field of business, entrepreneurship, personal development, health, wellness, and travel for women



Litigation Trends

Patent

- Coretek Licensing LLC v. Maven Clinic Co., Case No. 1:22-cv-08109 (S.D.N.Y.)
- Novoluto GmbH v. Uccellini LLC, Case No. 6:20-cv-02284 (D. Or.)
- Sportbrain Holdings LLC v. Bellabeat Inc., Case No. 1:17-cv-04281 (N.D. III.)

Trademark

- NeighborFavor Inc. v. Hey Favor, Inc., Case No. 1:22-cv-00618 (W.D. Tex.)
- TherapeuticsMD, Inc. v. Evofem Biosciences, Inc., Case No. 9:20-cv-82296 (S.D. Fla.)



VS.



Kythera Biopharmaceuticals Inc. v. Lithera Inc., Case No. 2:13-cv-06338 (C.D. Cal.)



M&A Trends

8 of the 81 are companies surveyed were acquired by/merged with:



- Proctor & Gamble (This is L. 2019)
- Kimberly-Clark (Thinx 2022)
- Unified Women's Healthcare (Gennev 2022)
- Apricity (WOOM 2022)
- Femtec Health (Ava 2022)
- Ro (Modern Fertility 2022)
- Bayer (kaNDy Therapeutics 2020)
- Thirty Madison (Nurx 2022)
- Everly Health (Natalist 2021)







Citations

- 1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC198535/
- 2. Perez, Caroline Criado, Invisible Women: Data Bias in a World Designed for Men, New York: Abrams Press, 2019, citing multiple sources, p. 199
- 3. https://www.fda.gov/media/71495/download
- 4. Christiana Vitale et al. (2017), 'Under-representation of elderly and women in clinical trials,' International Journal of Cardiology, 232, 216-221; Pamela E. Scott et al., "Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs," Journal of the American College of Cardiology 71, no. 18 (2019). doi: 10.1016/j.jack.2018.02.070.
- 5. Invisible Women, p. 205.
- 6. Karp, Natasha A. et al (2017), 'Prevalence of sexual dimorphism in mammalian phenotypic traits,' Nature Communications, 8:15475
- 7. Joel D. Greenspan et al., "Studying Sex and Gender Differences in Pain and Analgesia: A Consensus Report," Pain 132, Suppl. 1 (2007): S26-S45,
- 8. Hughes, Robert N. (2007) 'Sex does matter: comments on the prevalence of male-only investigations of drug effects on rodent behavior,' Behavioral Pharmacology, 18:7, 583-9.
- 9. Gao-01-286R Drug Safety: Most Drugs Withdrawn in Recent Years Had Greater Health Risks for Women," GAO.gov, https://www.gao.gov/assets/100/90642.pdf
- 10. McGregor, Alyson J., Sex Matters: How Male-Centric Medicine Endangers Women's Health and What We Can Do About It, New York: Hachette Books, 2020, p. 83; Paul M. Ridker, "The JUPITER Trial: Results, Controversies, and Implications for Prevention," Circulation: Cardiovascular Quality and Outcomes 2(2009): 279-285.
- 11. McGregor, Alyson J. (2017), 'The Effects of Sex and Gender on Pharmacological Toxicity: Implications for Clinical Therapy,' Clinical Therapeutics, 39:1.
- 12. Koning, Rembrand, Sampsa Samila, and John-Paul Ferguson. "Who Do We Invent for? Patents by Women Focus More on Women's Health, but Few Women Get to Invent." Working Paper. (Harvard Business School Working Paper, No. 19-124, June 2019; SSRN Working Paper Series, No. 3401889, June 2019.)
- 13. https://news.nationalgeographic.com/news/2013/13/130519-gomwn-scientists-verlooked-dna-history-science/
- 14. https://www.newm.cam.ac.uk/about/history/biographies/
- 15. Invisible Women, p. 17.
- https://www.bbc.com/news/technology-62877930
- https://fortune.com/2022/06/10/world-built-for-men-women-bodies-gender-gap-health-research-medicine-care-jain-bruzek/
- https://www.pewresearch.org/fact-tank/2022/09/26/women-now-outnumber-men-in-the-u-s-college-educated-labor-force/
- https://www.census.gov/library/stories/2021/01/women-making-gains-in-stem-occupations-but-still-underrepresented.html
- https://www.forbes.com/sites/markkantrowitz/2022/04/07/women-achieve-gains-in-stem-fields/?sh=68d179145ac5
- https://ipwatchdog.com/2022/07/27/uspto-expand-initiatives-resourced-inventors-first-time-filers/id=150440/#
- https://www.wipo.int/women-and-ip/en/news/2022/news 0001.html
- https://www.uspto.gov/sites/default/files/documents/OCE-DH-Progress-Potential-2020.pdf

■ https://pitchbook.com/news/articles/femtech-sector-venture-capital-weekend-analysis ht ps://www3.wipo.int/ipstats/pmhbarchart FISH & RICHARDSON



Questions?



Giordana Mahn Of Counsel gmahn@fr.com



Jacqueline Tio Principal tio@fr.com

Thank You!

Please send your NY/NJ CLE forms to mcleteam@fr.com

Any questions about the webinar, contact Michelle Zazzero at zazzero@fr.com

A replay of the webinar will be available for viewing at http://www.fr.com/webinars

© Copyright 2022 Fish & Richardson P.C. The opinions expressed are those of the authors and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This presentation is for general information purposes and is not intended to be and should not be taken as legal advice and does not establish an attorney-client relationship.

These materials may be considered advertising for legal services under the laws and rules of professional conduct of the jurisdictions in which we practice.. Legal advice of any nature should be sought from legal counsel. Unsolicited e-mails and information sent to Fish & Richardson P.C. will not be considered confidential and do not create an attorney-client relationship with Fish & Richardson P.C. or any of our attorneys. Furthermore, these communications and materials may be disclosed to others and may not receive a response. If you are not already a client of Fish & Richardson P.C., do not include any confidential information in this message. For more information about Fish & Richardson P.C. and our practices, please visit www.fr.com.

